FMP
REGENXBIO Inc.
RGNX
NASDAQ
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
5.89 USD
0.48 (8.15%)
2024
2023
2022
2021
83.33M
90.24M
112.72M
470.35M
33.57M
37.21M
54.55M
51.83M
49.76M
53.03M
58.18M
418.51M
283.11M
321.16M
321.06M
258.53M
208.52M
232.27M
242.45M
181.44M
76.62M
88.49M
85.28M
79.33M
0
0
0
0
76.62M
88.49M
85.28M
79.33M
-2.03M
397k
-6.68M
-2.24M
-233.35M
-268.13M
-262.88M
159.98M
6.24M
4.48M
-17.53M
-18.73M
-227.1M
-263.65M
-280.4M
141.25M
0
-152k
-84k
13.41M
-227.1M
-263.49M
-280.32M
127.84M
-4.59
-6.02
-6.5
3.01
-4.59
-6.02
-6.5
2.91
49.51M
43.73M
43.15M
42.44M
49.51M
43.73M
43.15M
43.91M
-198.23M
-239.46M
-244.24M
169.54M
All figures are in USD.